NCT04416737View on ClinicalTrials.gov

Evaluating the Benefits of Physiologic Insulin Delivery

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

June 2, 2023

Study Completion Date

June 2, 2023

Conditions
Type 1 Diabetes
Interventions
DRUG

Ultra-rapid insulin

Following 0.5-3 hours of insulin suspension from insulin pump, participants will receive insulin injection in respective locations (separated by at least 1 week) and then have serial lab measurements (YSI glucose, insulin and glucagon) taken during induced hypoglycemia.

Trial Locations (1)

94304

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Stanford University

OTHER

NCT04416737 - Evaluating the Benefits of Physiologic Insulin Delivery | Biotech Hunter | Biotech Hunter